Date: 16-Aug-2019

Faulty manufacturing trips up Nektars Bristol-partnered cancer drug in crucial trial

Could a manufacturing mix-up be as detrimental as the fact that a drug simply doesnt work? Nektar learned the answer the hard way with its Bristol-Myers Squibb-partnered experimental cancer therapy. On Thursday, Nektar CEO Howard Robin went to great lengths to explain why response rates dropped in the second stage of a clinical trial testing NKTR-214 (bempegaldesleukin) in tandem with Bristols Opdivo.